Cardiac diseases, such as myocardial infarction and heart failure, have become a major
clinical problem globally. The accumulating data demonstrate that bioactive compounds with …

Metabolic disorders like diabetes mellitus, hypertension, dyslipidemia, and obesity are major
medical problems globally. The incidence of these disorders has increased tremendously in …

Rutin is a flavonoid with antioxidant property. It has been shown to exert cardioprotection
against cardiomyocyte hypertrophy. However, studies regarding its antihypertrophic property …

Abnormality in myocardial copper homeostasis is believed to contribute to the development
of cardiomyopathy. Trientine, a copper-chelating drug used in the management of patients …

Cardiac hypertrophy is characteristic of heart failure in patients who have experienced
cardiac remodeling. Many medicinal plants, including Parkia speciosa Hassk., have …

The NOX family consists of seven isoenzymes that produce reactive oxygen species (ROS)
from molecular oxygen. Changes in redox balance may impact disorders linked to metabolic …

Cardiac hypertrophy is an early hallmark during the clinical course of heart failure.
Therapeutic strategies aiming to alleviate cardiac hypertrophy via the mitogen-activated …

Diabetic cardiomyopathy is a significant and severe complication of diabetes that affects a
large portion of the global population, with its prevalence continuing to rise. Secondary …

Purpose Cardiac dysfunction can occur as a sequela of a state of prolonged pressure
overload and postischemic injury. Flavonoids such as quercetin may be protective against …

Background Cardiovascular problems, particularly hypertension, are the leading causes of
mortality and disability. The pathogenesis of high blood pressure involves the dysregulation …